<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02360631</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00000721</org_study_id>
    <secondary_id>R01DA035796</secondary_id>
    <nct_id>NCT02360631</nct_id>
  </id_info>
  <brief_title>Advancing Tobacco Use Treatment for African American Smokers</brief_title>
  <acronym>KIS-IV</acronym>
  <official_title>Advancing Tobacco Use Treatment for African American Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lisa Sanderson Cox, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine whether or not providing Chantix (varenicline) will
      help African American smokers quit smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To have an impact on the premature mortality of African American smokers, effective treatment
      for smokers across the smoking continuum must be identified. Varenicline, the leading
      first-line medication for tobacco use treatment, triples the likelihood of long-term
      abstinence relative to placebo in those smoking &gt;10 cpd. To date, efficacy of varenicline has
      not been established in African American smokers or light smokers. The long-term goal of this
      research is to advance treatment for all African American smokers in order to reduce
      tobacco-related disease and death. Our primary objective is to evaluate the efficacy of
      varenicline for tobacco use treatment among 500 African American smokers, including a full
      range of cpd, within a double-blind, placebo-controlled, randomized clinical trial. We will
      randomize participants in a 3:2 ratio to receive varenicline (1 mg bid; n=300) or placebo
      (n=200) for 12 weeks, along with individualized health education counseling for all
      participants. Our specific aims are to evaluate the efficacy of varenicline to promote
      abstinence in African American smokers across the continuum of smoking level, to examine
      efficacy in light smokers and also in moderate to heavy smokers, and to describe
      biopsychosocial characteristics of this group and evaluate in relation to abstinence. This
      innovative study will provide the first placebo-controlled evaluation of varenicline in the
      full spectrum of African American smokers, and the first to examine varenicline in light
      smokers. Findings will contribute to advancing effective treatment for African American
      smokers and for light smokers, and enhancing individualized treatment. Increased treatment
      efficacy will have major impact on reducing tobacco-related morbidity and mortality in this
      high-risk population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 29, 2015</start_date>
  <completion_date type="Actual">July 12, 2018</completion_date>
  <primary_completion_date type="Actual">July 12, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Smoking Abstinence at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Month 6 visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Smoking Abstinence at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Week 12 visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Smoking Abstinence at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>Intent to treat Cotinine verified cessation for light and moderate to heavy smokers by treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">500</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Chantix (varenicline)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 1mg pills to take twice a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a placebo pill to take twice a day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chantix</intervention_name>
    <description>A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.</description>
    <arm_group_label>Chantix (varenicline)</arm_group_label>
    <other_name>Varenicline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Health education counseling will be provided to all participants.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Self-identified African American

          -  Smokes ≥ 1 cigarette per day (cpd)

          -  Smoke on ≥ 25 days of the past 30 days

          -  Functioning telephone

          -  Interested in quitting smoking

          -  Interested in taking 3 months of varenicline

          -  Willing to complete all study visits

        Exclusion Criteria:

          -  Renal impairment

          -  Evidence or history of clinically significant allergic reactions to varenicline

          -  A cardiovascular event in the past month

          -  History of alcohol or drug dependence in the past year

          -  Major depressive disorder in the last year requiring treatment

          -  History of panic disorder, psychosis, bipolar disorder, or eating disorders

          -  Use of tobacco products other than cigarettes in past 30 days

          -  Use of pharmacotherapy in the month prior to enrollment, including prior use of
             varenicline

          -  Pregnant, contemplating getting pregnant, or breastfeeding

          -  Plans to move from Kansas City during the treatment and follow-up phase

          -  Another household member enrolled in the study

          -  Evidence of current severe major depressive disorder or suicidal ideation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Sanderson Cox, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swope Health Central</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <results_first_submitted>June 5, 2019</results_first_submitted>
  <results_first_submitted_qc>July 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 24, 2019</results_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Lisa Sanderson Cox, PhD</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <keyword>smoking</keyword>
  <keyword>quit smoking</keyword>
  <keyword>smoking treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT02360631/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Chantix (Varenicline)</title>
          <description>Participants will receive 1mg pills to take twice a day for 12 weeks.
Chantix: A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants will receive a placebo pill to take twice a day for 12 weeks.
Placebo: Health education counseling will be provided to all participants.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="300"/>
                <participants group_id="P2" count="200"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Week 12</title>
              <participants_list>
                <participants group_id="P1" count="249"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="267"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Chantix (Varenicline)</title>
          <description>Participants will receive 1mg pills to take twice a day for 12 weeks.
Chantix: A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants will receive a placebo pill to take twice a day for 12 weeks.
Placebo: Health education counseling will be provided to all participants.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="300"/>
            <count group_id="B2" value="200"/>
            <count group_id="B3" value="500"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.6" spread="11.9"/>
                    <measurement group_id="B2" value="52.4" spread="11.0"/>
                    <measurement group_id="B3" value="51.9" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="156"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Employed</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" spread="7.1"/>
                    <measurement group_id="B2" value="30.1" spread="7.6"/>
                    <measurement group_id="B3" value="30.4" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes per day</title>
          <units>cigarettes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.9" spread="6.9"/>
                    <measurement group_id="B2" value="12.2" spread="6.2"/>
                    <measurement group_id="B3" value="12.6" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Smoking Abstinence at Month 6</title>
        <description>Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Month 6 visit</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chantix (Varenicline)</title>
            <description>Participants will receive 1mg pills to take twice a day for 12 weeks.
Chantix: A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a placebo pill to take twice a day for 12 weeks.
Placebo: Health education counseling will be provided to all participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Smoking Abstinence at Month 6</title>
          <description>Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Month 6 visit</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Smoking Abstinence at Week 12</title>
        <description>Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Week 12 visit</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Chantix (Varenicline)</title>
            <description>Participants will receive 1mg pills to take twice a day for 12 weeks.
Chantix: A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a placebo pill to take twice a day for 12 weeks.
Placebo: Health education counseling will be provided to all participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Smoking Abstinence at Week 12</title>
          <description>Biochemically verified 7-day point prevalence abstinence defined as smoking zero cigarettes at Week 12 visit</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Smoking Abstinence at Week 26</title>
        <description>Intent to treat Cotinine verified cessation for light and moderate to heavy smokers by treatment</description>
        <time_frame>Week 26</time_frame>
        <population>300 participants received varenicline and of those 154 were Light smokers (10 or less cigarettes per day (CPD) and 146 were moderate to heavy smokers (greater than 10 )CPD. 200 participants received placebo medication and of those 106 were light smokers and 94 were moderate to heavy smokers.</population>
        <group_list>
          <group group_id="O1">
            <title>Chantix (Varenicline)</title>
            <description>Participants will receive 1mg pills to take twice a day for 12 weeks.
Chantix: A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants will receive a placebo pill to take twice a day for 12 weeks.
Placebo: Health education counseling will be provided to all participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Smoking Abstinence at Week 26</title>
          <description>Intent to treat Cotinine verified cessation for light and moderate to heavy smokers by treatment</description>
          <population>300 participants received varenicline and of those 154 were Light smokers (10 or less cigarettes per day (CPD) and 146 were moderate to heavy smokers (greater than 10 )CPD. 200 participants received placebo medication and of those 106 were light smokers and 94 were moderate to heavy smokers.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
                <count group_id="O2" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Light</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="154"/>
                    <count group_id="O2" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heavy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="146"/>
                    <count group_id="O2" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was systematically collected between weeks 0-16.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chantix (Varenicline)</title>
          <description>Participants will receive 1mg pills to take twice a day for 12 weeks.
Chantix: A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants will receive a placebo pill to take twice a day for 12 weeks.
Placebo: Health education counseling will be provided to all participants.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="276" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="178" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="163" subjects_affected="163" subjects_at_risk="300"/>
                <counts group_id="E2" events="90" subjects_affected="90" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Gas or flatulence</sub_title>
                <counts group_id="E1" events="191" subjects_affected="191" subjects_at_risk="300"/>
                <counts group_id="E2" events="130" subjects_affected="130" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="120" subjects_affected="120" subjects_at_risk="300"/>
                <counts group_id="E2" events="78" subjects_affected="78" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue or Loss of Energy</sub_title>
                <counts group_id="E1" events="163" subjects_affected="163" subjects_at_risk="300"/>
                <counts group_id="E2" events="112" subjects_affected="112" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Trouble sleeping</sub_title>
                <counts group_id="E1" events="190" subjects_affected="190" subjects_at_risk="300"/>
                <counts group_id="E2" events="117" subjects_affected="117" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="157" subjects_affected="157" subjects_at_risk="300"/>
                <counts group_id="E2" events="95" subjects_affected="95" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="146" subjects_affected="146" subjects_at_risk="300"/>
                <counts group_id="E2" events="93" subjects_affected="93" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="95" subjects_affected="95" subjects_at_risk="300"/>
                <counts group_id="E2" events="62" subjects_affected="62" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="183" subjects_affected="183" subjects_at_risk="300"/>
                <counts group_id="E2" events="129" subjects_affected="129" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Change in hostility or aggression</sub_title>
                <counts group_id="E1" events="99" subjects_affected="99" subjects_at_risk="300"/>
                <counts group_id="E2" events="79" subjects_affected="79" subjects_at_risk="200"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="167" subjects_affected="167" subjects_at_risk="300"/>
                <counts group_id="E2" events="111" subjects_affected="111" subjects_at_risk="200"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Findings cannot be generalized to non-US Blacks and require replication with smokers outside the Midwestern US.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Lisa Sanderson Cox</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>913-588-2643</phone>
      <email>lcox@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

